Does prednisone help multiple myeloma?
Corticosteroids, such as dexamethasone and prednisone, are an important part of the treatment of multiple myeloma. They can be used alone or combined with other drugs as a part of treatment. Corticosteroids are also used to help decrease the nausea and vomiting that chemo might cause.
Is melphalan a chemotherapy drug used in the treatment of multiple myeloma?
Melphalan (U.S. brand name Alkeran) is a chemotherapy drug commonly used in treating multiple myeloma. It belongs to the class of drugs known as alkylating agents, which inhibit DNA and RNA synthesis, causing the death of both dividing and non-dividing tumor cells.
What is second line treatment for multiple myeloma?
Second-line therapy may involve: daratumumab, bortezomib and dexamethasone. lenalidomide and dexamethasone. carfilzomib and dexamethasone.
How long is Velcade treatment for multiple myeloma?
Velcade is given for nine 6-week treatment cycles.
Why are steroids used to treat multiple myeloma?
Dexamethasone and the other steroids are useful in myeloma treatment because they can stop white blood cells from traveling to areas where cancerous myeloma cells are causing damage. This decreases the amount of swelling or inflammation in those areas and relieves associated pain and pressure.
Will I lose my hair with melphalan?
You may have some thinning of your hair but it is unlikely that you will lose it completely. Thinning or loss of your hair will usually start within two to four weeks of your first dose of melphalan. You may also have thinning or loss of eyelashes, eyebrows and other body hair.
How long does diarrhea last after melphalan?
Ninety-seven percent of patients experienced diarrhea ranging 1 – 18 daily bowel movements (Figure 1) and lasting 0 – 17 days (median 7).
How do you know when multiple myeloma is in remission?
Remission after transplantation — The strict definition of remission requires that there are no signs or symptoms of multiple myeloma and that highly sensitive tests cannot detect any abnormal plasma cells. This type of remission occurs in about 50 to 60 percent of people after autologous transplantation.
How many times can you go into remission with myeloma?
About one-fourth of people with relapsed multiple myeloma will go into remission after several cycles of chemo. Those who get targeted therapies or high-dose chemo followed by a stem cell transplant usually have better outcomes. Clinical trial. You might want to consider this if your cancer comes back.
Do you lose your hair with Velcade?
Hair loss. Hair loss isn’t a direct side effect of Velcade, but it may be a side effect of other drugs used with Velcade. For example, hair loss may occur in people using Velcade with cyclophosphamide, which is a cytotoxic drug.
Why is Decadron given with Velcade?
The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma among patients who do not intend to immediately undergo a stem cell transplant according to clinical trial results …
What is the VMP regimen for multiple myeloma?
The VMP regimen has been studied as initial therapy for multiple myeloma, particularly in elderly patients who are not eligible for HDT-HSCT. Current guidelines recommend it as a preferred regimen for previously untreated patients who are not eligible for HDT-HSCT.
Which medications are used in the treatment of multiple myeloma (MM)?
VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA Study. J Clin Oncol. 2009;27(36):6086–6093.
Can bortezomib be used as a second line treatment for multiple myeloma?
Abstract The introduction of bortezomib, a novel first-in-class proteasome inhibitor, has been a major break through in the treatment of multiple myeloma. It is currently approved for the treatment of myeloma in the relapsed setting post transplant or as a second line treatment in patients unsuitable for transplantation.
What is the first proteasome inhibitor to be approved for myeloma?
Bortezomib is the first proteasome inhibitor to be approved for the treatment of myeloma and represents a step forward in the management of these patients.
